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a b s t r a c t 
In the central nervous system, alteration of glial cell differentiation can affect brain functions. Polychlo-
rinated biphenyls (PCBs) are persistent environmental chemical contaminants that exert neurotoxic ef-
fects in glial and neuronal cells. We examined the effects of a commercial mixture of PCBs, Aroclor1254
(A1254) on astrocytic differentiation of glial cells, using the rat C6 cell line as in vitro model. The exposure
for 24 h to sub-toxic concentrations of A1254 (3 or 9 μM) impaired dibutyryl cAMP-induced astrocytic
differentiation as showed by the decrease of glial ﬁbrillary acidic protein (GFAP) protein levels and inhi-
bition in change of cell morphology toward an astrocytic phenotype. The A1254 inhibition was restored
by the addition of a protein kinase C (PKC) inhibitor, bisindolylmaleimide (bis), therefore indicating that
PCBs disturbed the cAMP-induced astrocytic differentiation of C6 cells via the PKC pathway. The phos-
phorylation of signal transducer and activator of transcription 3 (STAT3) is essential for cAMP-induced
transcription of GFAP promoter in C6 cells. Our results indicated that the exposure to A1254 (3 or 9 μM)
for 24 h suppressed cAMP-induced STAT3 phosphorylation. Moreover, A1254 reduced cAMP-dependent
phosphorylation of STAT3 requires inhibition of PKC activity. Together, our results suggest that PCBs
induce perturbation in cAMP / PKA and PKC signaling pathway during astrocytic differentiation of glial
cells. 
C © 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical
Societies. Open access under CC BY-NC-SA license.Abbreviations: PCBs, polychlorinated biphenyls; dbcAMP, N 6 ,2 ′ - O -dibutyryl cAMP; 
A1254, Aroclor 1254; DMSO, dimethyl sulfoxide; DMEM, Dulbecco ’ s Modiﬁed Eagle ’ s 
Medium; MTT, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide; 
NMDA, N-methyl- d -aspartate; nNOS, neuronal nitric oxide; CNS, central nervous 
system; ROS, reactive oxygen species; GFAP, glial ﬁbrillary acidic protein; GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase; DAPI, 4 ′ ,6-diamidino-2-phenylindole; 
PKA, protein kinase A; PKC, protein kinase C; bis, 2-[1-(3-dimethylamino-propyl)indol- 
3-yl]-3-(indol-3-yl) maleimide; STAT3, signal transducer and activator of transcription 
3; CRE, cAMP responsive element; CREB, cAMP-response element binding protein; TRE, 
CRE transcriptional response element. 
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http://dx.doi.org/10.1016/j.fob.2013.10.008 1. Introduction 
Astrocytes, the main class of neuroglia, are the most abundant
cells in the central nervous system (CNS) providing an architecture
for neurons and secreting growth factors and cytokines in the re-
sponse to injury [ 1 ]. Besides, astrocytes are the major cell type that
preferentially sequestrates metals and accumulates toxic agents [ 2 ],
therefore suggesting a possible role in the control and / or modulation
of neurotoxic effects. 
Polychlorinated biphenyls (PCBs) are widespread and persistent
environmental contaminants accumulating in food chain in polluted
areas [ 3 ] that can affect nervous system development and functions
[ 4 ]. PCBs were produced for use as non-ﬂammable dielectrics in elec-
tronic parts, lubricants, plasticizers, vehicles for pesticide application,
and pigment suspension agents in carbonless copy paper [ 5 ]. PCBs
produce neurochemical alterations in several experimental models
[ 6 ], behavioral changes in learning, motor activity and sexual behav-
ior [ 7 ]. In addition, PCBs greatly affect cell viability, brain functions
and have been associated with neurodegenerative disorders [ 8 ]. PCBs
induce mitochondrial dysfunction and reactive oxygen species (ROS)
production [ 9 ] and in turn, alterations of dopaminergic neurons [ 10 ],an Biochemical Societies. Open access under CC BY-NC-SA license.
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aeath of cerebellar granule cells via N-methyl- d -aspartate (NMDA) re- 
eptor activation [ 11 ] and of neuroblastoma cells via the involvement 
f neuronal nitric oxide (nNOS) [ 12 ]. Furthermore, chronic exposure 
o these pollutants can affect the development of the CNS [ 4 ] and neu- 
onal plasticity [ 13 ]. Aroclor 1254 (A1254), a commercial mixture of 
CBs [ 14 ], most commonly found in various foods and in human spec- 
mens at contaminated sites [ 15 ], has been widely utilized in studying 
CBs toxicity [ 9 –14 ]. 
Although several scientiﬁc studies have been conducted on the 
eurotoxicity triggered by PCBs, the effects of these pollutants on 
strocytic differentiation has been poorly investigated. The rat C6 
lial cell line [ 16 ] has been widely used as model for study of factors 
hat modulate differentiation of glial cells [ 17 ]. The treatment of C6 
ells with dibutyryl(db)-cAMP, leads to inhibition of cell growth and 
ncreased expression of the astrocytic marker glial ﬁbrillary acidic 
rotein (GFAP) correlated to change in cell morphology from an 
pithelial-like to a process-bearing morphology [ 18 ]. In this study, 
e determined A1254 cytotoxicity and the effects of sub-toxic con- 
entrations on dbcAMP-induced astrocytic differentiation in C6 cells, 
y evaluation of GFAP levels and monitoring cell morphology. 
Furthermore, since protein kinase C (PKC) signaling is involved 
n A1254 neurotoxicity [ 19 –21 ], we also assessed the effects of a 
elective PKC inhibitor [ 21 , 22 ] on A1254-induced toxic effects. cAMP- 
nduced GFAP expression in C6 cells also requires activation of signal 
ransducer and activator of transcription 3 (STAT3) pathway [ 23 , 24 ], 
e also investigated the effect of A1254 on the activation status of 
TAT3. 
. Materials and methods 
.1. Materials 
Aroclor 1254 (Cat. N. 48586, Lot N. LB58885) was purchased 
rom Supelco (Italy, 99% purity) and dissolved in dimethyl sulfox- 
de (DMSO, cell culture tested, Sigma–Aldrich, Italy). The protein 
inase C (PKC) inhibitor, 2-[1-(3-dimethylamino-propyl)indol-3-yl]- 
-(indol-3-yl) maleimide (bis) was purchased from Cell Signaling 
echnology (Cat. N. 9841, Euroclone, Italy) and dissolved in DMSO. 
-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide, 
TT and N 6 ,2 ′ - O -dibutyryl cAMP (dbcAMP) were obtained from (Cat. 
. D0260, Sigma–Aldrich, Italy). 
.2. Cell cultures and treatments 
The C6 rat glial cell line [ 16 ] (American Type Culture Collection, 
TTC CCL-107) was cultured in Dulbecco’s Modiﬁed Eagle’s Medium 
DMEM) supplemented with 10% heat-inactivated fetal bovine serum 
FBS) (Invitrogen, Life Technologies, Italy), 1.5 mM l -glutamine, 
00 units / ml penicillin, and 100 μg / ml streptomycin under humidi- 
ed atmosphere of 5% CO 2 at 37 
◦C. Cells were sub-cultured twice a 
eek by 3–5-fold dilution with culture medium. Treatments of sub- 
onﬂuent cells were performed replacing the culture medium with 
hose containing increasing concentrations of A1254 (0.05–90 μM) or 
rotein kinase C inhibitor, bisindolylmaleimide [ 21 , 22 ] (0.05–12 μM). 
strocytic differentiation was induced using serum-free DMEM con- 
aining 1 mM dbcAMP. Co-exposure experiments were performed by 
dding simultaneously A1254 (3 or 9 μM) and / or bis (0.125 μM) dur- 
ng dbcAMP (1 mM) stimulation of C6 cells for 24 h. All the treatments 
ere performed under serum-free conditions in presence of 0.1% (v / 
) DMSO used as vehicle for A1254 and bis. 
.3. Viability assay 
Cells were seeded onto 96-well plates (2 × 10 4 cells per well) and 
fter the treatments, their viability was evaluated as mitochondrial 
ctivity using the MTT assay [ 25 ]. Brieﬂy, the medium was removed and cells incubated with 100 μl MTT (0.5 mg / ml) for 1 h. After that, 
the solution was removed, formazan solubilized in 100 μl DMSO and 
the absorbance measured at 540 nm using a microplate reader (Lab- 
systems Multiskan, MS). Results were expressed as percentage of cell 
survival vs. control cells cultured in serum-free medium with 0.1% (v / 
v) DMSO (vehicle) (which represent the 100% survival). 
2.4. Immunocytochemistry and phase-contrast analysis 
Cells grown on coverslips were treated and ﬁxed by a 20 min ex- 
posure to cold 4% paraformaldehyde in PBS, and then subjected to 
immunocytochemistry and phase-contrast analysis. For immununo- 
cytochemistry, cells were permeabilized with 0.2% Triton X-100 in 
PBS for 5 min. After blocking with 10% donkey serum for 1 h, the 
coverslips were incubated with a mouse anti-GFAP antibody (Cat. N. 
G3893, Sigma–Aldrich, Italy), thereafter, a ﬂuorescein isothiocyanate 
(FITC)-secondary antibody (Jeckson-Li StarFish, Italy) was applied. 
After washing, coverslips were mounted with Vectashield medium 
containing 1.5 μg / ml 4 ′ ,6-diamidino-2-phenylindole (DAPI) (Vector 
Laboratories, CA, USA) to visualize the nuclei. Immunoﬂuorescence 
analysis was performed using a Leica DM LB microscope (Plan 20 × / 
0.40 objective) connected to a Leica DFC 345 FX digital camera and 
images were captured using the Leica Application Suite 3.6 software 
(Version 3.6.0) (Switzerland). Phase-contrast images were captured 
using a Zeiss Axiovert 40 CFL inverted microscope (Carl Zeiss, Mi- 
lan, Italy) (LD A-Plan 40 × / 0.50 Ph 2 objective). The microscope was 
equipped with a 12.1-megapixel CCD digital videocamera (Canon, 
PowerShot G9, Italy) with a digital image software (Remote Capture 
DC, Canon). Images were imported into ImageJ software 1.43u, NIH. 
2.5. Western blotting 
Cells seeded in 6-well plates (2 × 10 5 per well) were subjected to 
different treatments and then lysed at 4 ◦C in 50 mM Tris–HCl pH 8.0, 
150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Igepal, 0.5% sodium deoxico- 
late, protease (Roche, Italy) and phosphatase inhibitor cocktails (Cal- 
biochem, Italy). The total protein concentration was determined by a 
Bradford protein assay [ 26 ] using bovine serum albumin as a standard. 
Equal amounts of proteins (20 μg) were subjected to 12% SDS–PAGE 
performed as described by Laemmli [ 27 ]. The proteins were trans- 
ferred to a nitrocellulose membrane (BA85; Schleicher & Schull) and 
incubated with a primary antibody: mouse anti-GFAP, anti-mouse 
STAT3 (Cat. N. 9139), anti-rabbit phospho-STAT3 (Ser727) (Cat N. 
9134), anti-rabbit phospho-PKC substrates (Cat. N. 2261S) from Cell 
Signaling Technology (Euroclone, Italy) followed by incubation with 
an appropriated anti-mouse (Cat. N. 31430) or anti-rabbit (Cat. N. 
31460) peroxidase-conjugated secondary antibody (Pierce, Thermo 
Scientiﬁc, Italy) in PBS containing 5% dry milk. The signals were vi- 
sualized using an Enhanced Chemiluminescence (ECL) detection kit 
(Cat. N. RPN 2209, GE Healthcare, Italy). Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) antibody (Cat. N. AM4300, Ambion, Applied 
Biosystems, Italy) was used as protein loading control. Signal quan- 
tiﬁcation was performed with ImageJ software 1.43u, NIH. 
2.6. Statistical analysis 
Statistical signiﬁcance of treated samples against control cells 
(cultured in serum-free medium with vehicle 0.1% v / v DMSO) 
was determined by One-way analysis of Variance (ANOVA), fol- 
lowed by Dunnett’s test. Each value represents the mean ± SEM 
of at least three independent experiments performed in triplicate 
( * p < 0.05; § p < 0.01; # p < 0.001). 
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Fig. 1. Exposure to A1254 affected cell viability in a concentration and time-dependent 
manner in C6 cells. (A) Cells were exposed to increasing concentrations of A1254 
(0.05–90 μM) for 24 h in serum-free medium with 0.1% DMSO (vehicle). (B) C6 cells 
were treated with A1254 (3 or 9 μM) for 48 and 72 h. After incubation, cell viability 
was evaluated using the MTT assay, as described in Section 2.3 . The cell viability was 
calculated vs untreated control cells, cultured in serum-free-DMEM with 0.1% DMSO 
(vehicle) at the respective time of incubation (24, 48 or 72 h) set as 100%. Results 
are presented as percentage (mean ± SEM) ( n = 3) of the control cells. Signiﬁcant 
difference from the untreated control; * p < 0.05; § p < 0.01; # p < 0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Exposure to A1254 decreased dbcAMP-induced GFAP protein expression levels 
in C6 cells . Control and C6 cells treated with A1254 (3 or 9 μM) in presence or absence 
of dbcAMP (1 mM) were harvested after 24 h and assayed for GFAP protein expres- 
sion levels. Equal amounts of protein cell lysates (20 μg) were subjected to protein 
analysis by 12% SDS–PAGE. (A) Western blotting showing GFAP protein expression 
levels. GAPDH was used as loading control for cell lysates. Signals were revealed by 
immunostaining and ECL, as described in Section 2.5 . (B) Densitometric analysis of 
GFAP expression levels. Fold change in GFAP levels was calculated by ﬁrst normalizing 
to GAPDH levels in individual samples and then relative to untreated control (cells cul- 
tured in serum-free DMEM with 0.1% (v / v) DMSO, vehicle) set as 1. Each bar represents 
the mean ± SEM ( n = 3). Columns with (#) were statistically different from control 
and dbcAMP-differentiated cells ( # p < 0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3. Results 
3.1. Effect of A1254 exposure on C6 cell survival 
Cytotoxic effect of A1254 was assessed in C6 glial cells by treat-
ments with increasing amounts of the mixture, in agreement with
literature [ 21 ]. The exposure to increasing concentrations of A1254
(0.05–90 μM) for 24 h induced a concentration dependent reduction
of cell viability, evaluated as mitochondrial activity by MTT assay; the
addition of DMSO, used as vehicle for A1254, at a ﬁnal concentration
of 0.1% (v / v) by itself did not cause any cell toxicity ( Fig. 1 A). More-
over, the highest concentrations of A1254 (30, 45 and 90 μM) sig-
niﬁcantly ( p < 0.001) decreased the cell viability reaching a maximal
effect of 80–98% lethality. Based upon these results, the non-toxic
concentration of 3 μM and the concentration of 9 μM that caused
about 25% lethality were chosen to study the effect of a prolonged
treatment on cell viability. The concentration of A1254 3 μM caused
about 25–50% reduction on cell viability at 48 and 72 h. Furthermore,
the concentration of A1254 9 μM caused a higher decrease of cell
survival reduction of cell viability (about 50%) at 48 and 72 h ( Fig. 1 B).
Therefore, the concentrations of A1254 3 and 9 μM and an exposure
time of 24 h were used for the subsequent treatments for cellular and
biochemical studies. 
3.2. Effects of A1254 on dbcAMP-induced GFAP expression levels and 
astrocytic differentiation in C6 cells 
To examine whether the exposure to sub-toxic concentrations of
A1254 might affect dbcAMP induced GFAP expression levels, C6 cells
were exposed simultaneously to both agents and GFAP protein ex-
pression levels were determined by western blotting ( Fig. 2 ). C6 cells
cultured in DMEM with 10% FBS expressed low GFAP protein levelsthat were similar to those expressed by untreated cells cultured un-
der serum-free condition, with or without 0.1% (v / v) DMSO or cells
exposed to A1254 alone. The stimulation with dbcAMP (1 mM) for
24 h greatly elevated GFAP protein expression levels (about 8-fold
increase) according to previous results [ 18 ]. Cells co-exposed to db-
cAMP and A1254 showed an inhibition of GFAP expression; in par-
ticular, while the concentration of 3 μM A1254 did not signiﬁcantly
affect the GFAP protein levels (about 1.2-fold decrease), the 9 μM
led to a signiﬁcant decrease on GFAP expression levels (about 4-fold
decrease), in comparison with cells treated with dbcAMP alone. More-
over, the effects of A1254 on dbcAMP-induced GFAP expression and
astrocytic phenotype were evaluated by immunocytochemistry ( Fig.
3 ) and phase-contrast analysis ( Fig. 4 ). C6 cells cultured in DMEM
with 10% serum showed a very low GFAP immunoreactivity ( Fig. 3 ,
A–C) and had a ﬂat and epithelial-like undifferentiated morphology
( Fig. 4 , A). The treatment of C6 cells with 1 mM dbcAMP for 24 h, re-
sulted in differentiated astrocytic cells with round cell bodies and long
cell processes ( Fig. 4 , F), expressing a strong GFAP immunoreactivity
( Fig. 3 , P–R). In contrast, the co-exposure to A1254 (3 or 9 μM) and
dbcAMP impaired astrocytic differentiation. In fact, GFAP immunore-
activity was signiﬁcantly attenuated ( Fig. 3 , S–X) and a decrease of
the length of extended processes in each cell body was observed ( Fig.
4 , G and H), particularly at the concentration of 9 μM ( Fig. 3 , V–X; Fig.
4 , H). In the absence of dbcAMP, the addition of A1254 (3 or 9 μM)
did not inﬂuence either GFAP immunoreactivity ( Fig. 3 , J–O) or cell
morphology ( Fig. 4 , D and E) that were similar to that of control cells,
cultured in serum-free medium with ( Fig. 3 , G–I; Fig. 4 , C) or without
( Fig. 3 , D–F; Fig. 4 , B) 0.1% (v / v) DMSO (vehicle). These results indi-
cate that the exposure to sub-toxic concentrations of A1254 impair
dbcAMP-induced astrocytic differentiation in C6 cells. 
3.3. Effect of the protein kinase C inhibitor, bisindolylmaleimide, (bis) 
on A1254-inhibition of dbcAMP-stimulated GFAP expression levels in C6
cells 
Since PCBs neurotoxic effects have been reported to involve PKC
signaling [ 28 , 29 ], we evaluated whether a sel e ctive PKC inhibitor,
bis [ 21 , 22 ] might affect the A1254-induced impairment of dbcAMP-
induced GFAP expression and astrocytic morphology. 
We ﬁrst examined the affect of bis exposure on cell viability. To this
end, C6 cells were treated with increasing amounts of bis for 24 h, and
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Fig. 3. Effects of A1254 exposure on GFAP immunoreactivity in dbcAMP differentiating 
C6 cells. C6 cells were subjected to different treatments, ﬁxed and then immunocyto- 
chemistry was performed as detailed in Section 2.4 . C6 cells were cultured in DMEM 
with 10% FBS (A–C) or kept in serum-free DMEM in presence (G–I) or absence (D–F) of 
0.1% (v / v) DMSO (vehicle). Cells exposed to: 3 μM A1254 (J–L); 9 μM A1254 (M–O); 
1 mM dbcAMP (P–R). dbcAMP-differentiating cells exposed to A1254 3 μM (S–U) or 9 
μM (V–X). After the treatments, cells were subjected to GFAP immunostaining (green) 
(A, D, G, J, M, P, S and V). DAPI-nuclear stain (blue) of the same ﬁeld (B, E, H, K, N, Q, T 
and W). Merge for composite images (C, F, I, L, O, R, U and X). All the treatments were 
performed for 24 h under serum-free conditions in presence of 0.1% (v / v) DMSO used 
as vehicle for A1254. Scale bar = 50 μm. (For interpretation of color in Fig. 3, the reader 
is referred to the web version of this article.) 
Fig. 4. Effects of A1254 exposure on morphological change in dbcAMP-differentiating 
C6 cells. C6 cells were subjected to different treatments, ﬁxed and then subjected to 
phase- contrast analysis, as detailed in Section 2.4 . Phase-contrast micrographs of C6 
cells cultured in DMEM with 10% serum (A) or kept in serum-free DMEM with (C) or 
without (B) of 0.1% (v / v) DMSO (vehicle). Cells exposed to: 3 μM A1254 (D); 9 μM 
A1254 (E); 1 mM dbcAMP (F). dbcAMP-differentiating cells exposed to A1254 3 μM (G) 
or 9 μM (H). All the treatments were performed for 24 h under serum-free conditions 
in presence of 0.1% (v / v) DMSO, used as vehicle for A1254. Scale bar = 25 μm. 
Fig. 5. Effect of exposure to the protein kinase C inhibitor, bisindolylmaleimide, (bis) 
on C6 cell survival. (A) Concentration-dependent cytotoxic effects were evaluated by 
exposure for 24 h to increasing concentrations of A1254 (0.05–90 μM) in serum-free 
medium with 0.1% (v / v) DMSO (vehicle). (B) Effects of co - exposure to bis (0.125 μM) 
and A1254 (3 or 9 μM) of dbcAMP stimulated cells. Control treatments were performed 
as reported in the ﬁgure. After the treatments, cell survival was determined by MTT 
assay, as reported in Section 2.3 . Results are presented as percentage (mean ± SEM) ( n 
= 3) of the control cells cultured in serum-free DMEM with 0.1% (v / v) DMSO (vehicle) 
set as 100%. Signiﬁcant difference from the control; * p < 0.05; § p < 0.01. 
 then subjected to MTT assay ( Fig. 5 A). We observed a concentration- 
dependent cytotoxic effect, with an IC 50 value of 10 μM in agree- 
ment with the literature [ 21 ]. The concentration of 0.125 μM bis, 
that did not affect cell survival (about 98% viability), was chosen for 
further experiments. In addition, we also assessed cell viability after 
co-exposure to bis and A1254 (3 or 9 μM) in dbcAMP induced cells 
( Fig. 5 B). The treatment with bis (0.125 μM) in combination with 
dbcAMP (1 mM) did not affect signiﬁcantly cell viability (88% cell sur- 
vival) compared to untreated cells (serum-free DMEM with 0.1% (v / v) 
DMSO) as well as to cells stimulated with dbcAMP alone (96% cell via- 
bility). Interestingly, the co-exposure to bis (0.125 μM) and A1254 (3 
or 9 μM) in presence of dbcAMP did not change cell survival respect 
to A1254 alone (3 or 9 μM) ( Fig. 1 A) or in combination with bis ( Fig.
5 B). 
We then examined the effect of co-exposure to bis and A1254 on 
dbcAMP induced GFAP expression levels by western blotting ( Fig. 6 ). 
The treatment with bis was able to revert the decrease of GFAP levels 
triggered by A1254 in dbcAMP stimulated C6 cells, with a maximal re- 
covery (about 9-fold increase) for cells treated with 9 μM A1254. The 
treatment with bis (0.125 μM) alone did not change signiﬁcantly the 
basal expression of GFAP levels (about 1.6-fold increase) compared 
to that of untreated control cells (serum-free-DMEM with 0.1% (v / v) 
DMSO). 
The effect of bis (0.125 μM) was also evaluated on GFAP immunos- 
taining and morphological changes in C6 cells co-treated with db- 
cAMP (1 mM) and A1254 (3 or 9 μM) ( Fig. 7 ). The treatment with bis 
alone did not affect GFAP immunoreactivity ( Fig. 7 A, D–F) and cell 
morphology ( Fig. 7 B, B) was similar to that of control cells ( Fig. 7 A, 
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Fig. 6. Effect of the protein kinase C inhibitor, bisindolylmaleimide (bis) on GFAP 
protein expression levels in dbcAMP-stimulated C6 cells exposed to A1254. Cells were 
treated with bis (0.125 μM) or co-exposed to bis (0.125 μM) and A1254 (3 or 9 μM) in 
presence of dbcAMP (1 mM) in serum-deprived medium containing 0.1% (v / v) DMSO, 
used as vehicle for A1254 and bis. After 24 h incubation, treated and untreated control 
cells were harvested and assayed for GFAP protein expression levels. Equal amounts 
of protein cell lysates (20 μg) were subjected to protein analysis by 12% SDS–PAGE. 
(A) Western blotting showing GFAP protein expression levels. GAPDH was used as 
loading control for cell lysates. Signals were revealed by immunostaining and ECL, as 
described in Section 2.5 . (B) Densitometric analysis of GFAP protein expression levels. 
Fold change in GFAP protein levels was calculated by ﬁrst normalizing to GAPDH levels 
in individual samples and then relative to untreated control cells cultured in serum- 
free DMEM with 0.1% (v / v) DMSO, (vehicle) set as 1. Each bar represents the mean ±
SEM (n = 3). Columns with (#) were statistically different from untreated control cells 
or dbcAMP-differentiated cells (# p < 0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. Effect of co-exposure to A1254 and PKC inhibitor, bis, on dbcAMP-induced 
GFAP immunoreactivity and morphological change in C6 cells. C6 cells were subjected 
to different treatments, ﬁxed and then immunocytochemistry (A) and phase-contrast 
(B) analysis were performed as detailed in Section 2.4 . Cells were treated with bis (0.125 
μM) or co-exposed to bis (0.125 μM) and A1254 (3 or 9 μM) in presence of dbcAMP (1 
mM) in serum-deprived medium containing 0.1% (v / v) DMSO. After 24 h incubation, 
cells were subjected to immunoﬂuorescence analysis to reveal GFAP immunoreactivity 
(green). Immunocytochemistry of cells treated with 0.1% (v / v) DMSO (vehicle) (A–C); 
cells exposed to bis (0.125 μM) (D–F). Astrocytic differentiation induced by treatment 
with dbcAMP (1 mM) in presence of bis (0.125 μM) (G–I). dbcAMP-differentiated cells 
co-exposed to: bis (0.125 μM) and 3 μM A1254 (J–L): bis (0.125 μM) and 9 μM A1254 
(M–O). GFAP immunostaining (A, D, G, J and M). DAPI-nuclear stain (blue) of the same 
ﬁeld (B, E, H, K, and N). Merge for composite images (C, F, I, L and O). Scale bar = 50 μm. 
(B) Phase-contrast micrographs of C6 cells cultured in serum-free DMEM in presence 
(B) or absence (A) of bis (0.125 μM). dbcAMP-differentiating cells were treated with 
bis (0.125 μM) alone (C) or in combination with A1254 3 μM (D) or 9 μM (E). All the 
treatments were performed for 24 h under serum-free conditions in presence of 0.1% 
(v / v) DMSO used as vehicle for A1254 and bis. Scale bar = 25 μm. (For interpretation 
of color in Fig. 7, the reader is referred to the web version of this article.) 
 
 
 
 
 
 
 
 A–C; Fig. 7 B, A). Furthermore, the co-treatment with bis and dbcAMP
( Fig. 7 A, G–I; Fig. 7 B, C) did not inﬂuence dbcAMP induced astrocytic
differentiation (see Figs. 3 , P–R and 4 , F). Moreover, in presence of bis
and A1254 (3 or 9 μM), we observed a strong GFAP immunoreactiv-
ity ( Fig. 7 A, J–O) and extension of long astrocytic processes ( Fig. 7 B,
D and E). Taken together, these results strongly suggest the involve-
ment of PKC signalling in the impairment of astrocytic differentiation
triggered by A1254 in C6 cells. 
3.4. Effect of A1254 on PKC activity and cAMP-dependent activation of 
STAT3 
To conﬁrm that A1254 inhibits dbcAMP-stimulated astrocytic dif-
ferentiation via PKC pathway, the PKC activity was evaluated. We used
a Phospho-(Ser) PKC substrate antibody that recognizes the motif: Arg
or Lys-X-Ser phospho -Hyd-Arg or Lys in western blotting analysis per-
formed on total protein extracts from C6 cells subjected to different
treatments for 24 h ( Fig. 8 A). Undifferentiated C6 glioma cells (cul-
tured in serum-free DMEM–0.1% DMSO, with or without A1254, 3 or
9 μM) had a basal level of phosphorylation on several protein bands
that was more prominent on some bands (Mr of 200, 78, 65 and
28 kDa). The treatments with dbcAMP (1 mM) or bis (0.125 μM) and
the co-exposure to dbcAMP and bis in presence or absence of A1254 (3
or 9 μM) completely eliminated these phosphorylations. Conversely,
the co-exposure to dbcAMP and A1254, at the concentration of 9 μM,
led to a PKC activation, as revealed by the presence of phosphorylated
protein bands that had a pattern similar to that of undifferentiated
C6 cells. This ﬁnding indicated that A1254 effects are also mediated
by PKC activation that plays a critical role in counteracting the cAMP /
PKA positive signaling during astrocytic differentiation in C6 cells. 
Since cAMP induced GFAP expression in C6 cells is accompanied
with an increase in phosphorylation level of STAT3 (pSTAT3), which is
a transcription activator for GFAP promoter [ 23 , 24 , 30 ], next we exam-
ined whether PCBs treatment modulates the phosphorylation status
of STAT3 during dbcAMP induced astrocytic differentiation in C6 cells.
Our results ( Fig. 8 B) demonstrated that the stimulation with dbcAMP
(1 mM) for 24 h induced a great elevation in phosphorylation level of
STAT3 on Ser727 compared with that of undifferentiated C6 glial cells,
cultured in serum-free DMEM–0.1% DMSO, with or without A1254 (3
or 9 μM). The exposure to A1254 (3 and 9 μM) almost completelysuppressed dbcAMP induced STAT3 phosphorylation. The treatment
with the PKC inhibitor, bis, alone or in combination with dbcAMP, did
not alter the activation status of STAT3 compared to control and db-
cAMP stimulated cells. Interestingly, the co-exposure to A1254 and
bis of dbcAMP-stimulated cells increased either STAT3 protein and
phosphorylation levels, that were similar to those induced by db-
cAMP. This ﬁnding indicates that A1254 reduced cAMP-dependent
phosphorylation of STAT3 on Ser727 requires inhibition of PKC activ-
ity. 
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Fig. 8. Effects of A1254 treatment on PKC activity (A) and activation status of STAT3 
(B) in bis co-treated dbcAMP C6 cells. C6 cells were treated or not with A1254 (3 or 9 
μM) in presence or absence of the PKC inhibitor, bis (0.125 μM) during dbcAMP (1 mM) 
stimulation in serum-deprived medium containing 0.1% (v / v) DMSO, used as vehicle 
for A1254 and bis. After 24 h incubation, control and treated cells were harvested 
and equal amounts of protein cell lysates (20 μg) were separated by 12% SDS–PAGE 
and subjected to immunostaining, as described in Section 2.5 . (A) Western blotting 
using an anti-phospho-(Ser) PKC substrates showing PKC substrates phosphorylation. 
Arrows indicated the more abundant phosphorylated protein bands (Mr of 200, 78, 
65 and 28 kDa). (B) Western blotting showing phospho-Serine727 form of STAT3 and 
STAT3 total protein expression levels. GAPDH was used as loading control for cell 
lysates. Signals were revealed by immunostaining and ECL, as described in Section 2.5 . 
(C) Densitometric analysis of phospho-STAT3 and total protein expression levels; fold 
changes were calculated by ﬁrst normalizing to GAPDH levels in individual samples 
and then relative to untreated control (cells cultured in serum-free DMEM with 0.1% 
(v / v) DMSO, vehicle) set as 1. Each bar represents the mean ± SEM ( n = 3). Columns 
with (#) were statistically different from untreated control or dbcAMP-differentiated 
cells ( # p < 0.001). 
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Astrocytes are the main class of neuroglia involved in the regula- 
ion of brain microenvironment, in particular as regards neurotrans- 
itter and ionic homeostasis, metabolic support of neurons, regula- 
ion of energy metabolism, synaptic transmission and neuronal ex- 
itability, synaptic generation, detoxiﬁcation, free-radical scavenging, 
etal sequestration, development, and maintenance of blood–brain 
arrier, guidance of neuronal migration and immune function [ 31 ]. 
hese cells are among the ﬁrst lines of defense in the nervous sys- 
em and are involved in activities which maintain an environment 
ptimally suited for neuronal functions. 
A1254 and polybrominated diphenyl ethers (PBDEs), compounds 
hat have similar structure to PCBs, exert differential cytotoxic effects 
n human astrocytoma cells [ 20 ]. There are few studies in literature 
hat explain the role of PCBs on astrocytes, mainly the effect of PCBs 
ixture, called Aroclor, is poorly understood. 
We used the rat C6 glioma cell line that is commonly used to perform differentiation studies, because these cells possesses pro- 
genitor properties that reﬂect oligodendrocytic and astrocytic phe- 
notypes [ 32 , 33 ]. In addition, C6 cells have been extensively used for 
the study of factors and conditions which play a role in the prolif- 
eration and differentiation of glial cells [ 33 ]. In the present study, 
we ﬁrst demonstrated that the exposure to A1254 induced cytotoxic 
effect in C6 cells, in a concentration and time-dependent manner 
( Fig. 1 ). Interestingly, the IC 50 value was lower than that detected 
in neuroblastoma cell line [ 14 ], thus suggesting a higher sensitiv- 
ity of C6 glial cells to PCBs. However, the most intriguing ﬁnding of 
the present study is the evidence for a consistent down-regulation 
of dbcAMP-induced GFAP expression levels following exposure of C6 
cells to A1254 ( Figs. 2 and 3 ). These results strongly suggest that PCBs 
exposure is able to signiﬁcantly impair astrocytic differentiation of 
glial cells. Cell differentiation requires the modulation of multiple 
biochemical pathways that must be coordinate. The exposure of C6 
cells to dbcAMP is known to inhibit cell growth and to induce a change 
of morphology toward an astrocytic phenotype [ 34 ] as reﬂected by 
increased expression of the astrocytic markers, GFAP [ 35 , 36 ]. In C6 
cells, induction of GFAP synthesis is a crucial event that promotes cy- 
toskeleton reorganization required for the formation of spindle shape 
processes during astrocytic differentiation. The signaling cascade of 
cAMP-induced astrocytic differentiation is not yet fully elucidated, 
and the role of PKA in C6 cell differentiation is still under investiga- 
tion. Although all components of the PKA-CRE signaling pathway are 
present in C6 cells, some authors reported that cAMP-induced acti- 
vation of GFAP synthesis is independent of PKA activation [ 35 , 37 , 38 ]. 
In fact, the CRE-like sequence (TGACCTCA) present in the mouse and 
human GFAP promoters is not conserved in rat [ 39 –41 ] and no other 
CRE sequences are detected in the cAMP-dependent enhancer region 
of the GFAP promoter [ 37 ]. However, PKA plays an important part in 
GFAP induction via activation of the Jak-STAT3 pathway mediated by 
the transcription of cAMP-response element (CRE) genes in differen- 
tiated C6 cells [ 28 , 30 ]. 
Although some of the effects induced by cAMP are exerted through 
PKA, some actions have been reported to be mediated by PKC. In fact, 
in C6 cells, GFAP expression is also regulated by a PKC-dependent 
mechanism [ 35 , 42 ]. Besides, activation of PKC leads to the phospho- 
rylation of proteins which are involved in proliferation and differen- 
tiation of glial cells [ 43 , 44 ]. 
C6 cells express speciﬁc PKC isoforms that correlate to different 
phenotypes through modulation of GFAP expression: PKC α induces 
a strong inhibition of GFAP expression whereas PKC β and γ increase 
the expression of this protein [ 45 ]. 
In fact, it has been shown that in C6 cells the treatment with db- 
cAMP causes a decrease of PKC α isoform resulting in an increase of the 
astrocytic marker GFAP [ 45 ]. On the other hand, it has been demon- 
strated that PCBs are able to activate PKC translocation [ 27 , 46 ] and 
more recently, Madia et al. [ 20 ] have highlighted that A1254 exposure 
induces just the translocation of PKC α and ε isoforms. Therefore, it is 
plausible to suggest that the effect of PCBs on PKC isoforms antago- 
nizes that of dbcAMP resulting in the detected GFAP decrease with 
a consequent inhibition of astrocytic differentiation. This hypothesis 
was conﬁrmed using a speciﬁc inhibitor of PKC, bis, that reverted the 
impairment on dbcAMP differentiation triggered by A1254 in C6 cells 
( Figs. 6 and 7 ). 
As regards the possible molecular mechanism by which PCB s can 
affect astrocytic differentiation in C6 cells, we hypothesized that the 
reduction of GFAP expression levels exerted by PCBs might involve an 
effect of these agents on PKC synthesis and / or activity. The involve- 
ment of PKC in PCB-induced decrease of GFAP expression induced by 
dbcAMP is further proved by the results showing that while the treat- 
ment with dbcAMP (1 mM) completely eliminated phosphorylation 
of PKC-speciﬁc substrates, the co-exposure to dbcAMP and A1254, at 
the concentration of 9 μM, led to a PKC activation, as revealed by the 
presence of phosphorylated protein bands that had a pattern similar 
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 to that of undifferentiated C6 cells ( Fig. 8 A). This ﬁnding clearly in-
dicates that A1254 effects are also mediated by PKC activation that
plays a critical role in counteracting the cAMP / PKA positive signaling
during astrocytic differentiation in C6 cells. 
Another issue that deserves to be discussed is the effect of A1254
exposure on the well known increase of phosphorylation level of
STAT3 that accompanies cAMP-induced GFAP expression in glial and
C6 cells [ 28 , 30 ] and, how this effect may be associated with the in-
volvement of PKC in the mechanism of action of PCBs in our exper-
imental model. Indeed, the results of the present study showed that
A1254 exposure inhibited the increase of STAT3 phosphorylation in-
duced by cAMP and, the PKC inhibitor, bis, blocked this inhibition.
This result suggests that A1254-reduced cAMP-dependent phospho-
rylation of STAT3 on Ser727 requires inhibition of PKC activity ( Fig.
8 ). 
It is interesting to underline that in the same range of concentra-
tions, A1254 caused an inhibition of skeletal muscle differentiation
evaluated as fusion of myoblasts into multinucleated myotubes and
on the basis of the increase of creatine-kinase activity [ 47 ]. On the
other hand, it has been also demonstrated that PCBs could interfere
with the process of neural differentiation. In fact, it was found that
PCB 118, a congener known to widely contaminate human popula-
tion, might alter the course of oligodendrocyte formation in primary
Normal Human Neural Progenitor (NHNP) cells [ 48 ]. 
In summary, our results indicate that PCBs are cytotoxic to C6
glial cells and that, at sub-toxic concentrations, they may affect glial
differentiation causing either a reduction of GFAP expression levels
or an inhibition of change in cell morphology toward an astrocytic
phenotype. Furthermore, our results suggest that one of the possible
mechanisms involved in the negative effect exerted by PCBs on glial
differentiation might be an interference with PKC pathway. Further
studies will be necessary to clarify whether regulation of GFAP ex-
pression can be mediated by direct effect of PKC / PKA on this protein,
a cross-talk between them or indirectly by interactions with other
signaling pathway. 
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